Trials / Unknown
UnknownNCT05145218
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
A Multicenter, Randomized, Open, Parallel Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Androtinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment in the Treatment of Recurrent Platinum-resistant Ovarian Cancer
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 405 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405 subjects will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib Hydrochloride Capsules | Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor. |
| DRUG | Paclitaxel injection | Paclitaxel is a novel anti-microtubule agent. |
| DRUG | TQB2450 injection | TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody. |
Timeline
- Start date
- 2021-09-28
- Primary completion
- 2024-10-01
- Completion
- 2024-12-01
- First posted
- 2021-12-06
- Last updated
- 2021-12-08
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05145218. Inclusion in this directory is not an endorsement.